<DOC>
	<DOCNO>NCT02455167</DOCNO>
	<brief_summary>1 . Achieve sustain virologic response ( SVR ) patient infect HCV genotype 1 , cirrhosis , early clinical decompensation use 12 week Olysio/Sovaldi/Ribavirin ( know : Simeprevir ( SMV ) /Sofosbuvir ( SOF ) /Ribavirin ( RBV ) . 2 . Hepatic improvement Simeprevir ( SMV ) /Sofosbuvir ( SOF ) /Ribavirin ( RBV ) treatment use new test liver function , HepQuant-SHUNT .</brief_summary>
	<brief_title>Reversal Hepatic Impairment Patients With Hepatitis C Virus ( HCV ) Early Decompensation Cirrhosis</brief_title>
	<detailed_description>The propose study quantify hepatic improvement antiviral efficacy open-label interferon-free combination 12 week simeprevir ( SMV , Simeprevir ) , sofosbuvir ( SOF , Sofosbuvir ) , ribavirin ( RBV ) patient HCV genotype 1 infection early decompensation cirrhosis . Early decompensation define clinical complication laboratory deterioration model end-stage liver disease ( MELD ) score 10 less . The primary objective trial determination hepatic functional improvement measure HepQuant ( HQ ) test Simeprevir ( SMV ) /Sofosbuvir ( SOF ) /Ribavirin ( RBV ) . Standard laboratory test , clinical model ( MELD , CTP ) , liver biopsy , hepatic venous pressure gradient ( HVPG ) , image test insensitive , invasive , nonspecific . They may adequately assess liver 's improvement viral eradication . In contrast , HepQuant ( HQ ) test ( Systemic Hepatic Filtration Rate ( HFR ) , Portal HFR , SHUNT , single point cholate concentration ( STAT ) , DSI ) noninvasive , sensitive , specific , target endogenous function , hepatic uptake cholate . HQ test use serum sample time period 90 minute quantify systemic circulation , portal circulation , portal-systemic shunt derive disease severity index ( DSI ) intact human subject . The primary endpoint treatment trial improvement hepatic function measure HepQuant ( HQ ) test occurs successful Simeprevir ( SMV ) /Sofosbuvir ( SOF ) /Ribavirin ( RBV ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . HCV genotype 1 infection ( subtypes Q80K type mutation allow ) , approve third party payer FDAapproved combination sofosbuvir ( SOF ) plus ribavirin . The study drug , simeprevir ( SMV ) 2 . Biopsy proven cirrhosis , clinical cirrhosis APRI ( AST Platelet Ratio Index determine clinical cirrhosis ) &gt; 2 , Fibrotest &gt; 0.75 , Fibroscan &gt; 12.5 Results Stiffness ( kPa ) . 3 . MELD 10 less 4 . Expected survival without liver transplantation &gt; 1 year 5 . Patients Hepatocellular carcinoma ( HCC ) include long disease MELD 10 less , anticipated time transplant &gt; 1 year . An example , might patient subcentimeter HCC undergo serial imaging document tumor growth tumor diameter &gt; 2 cm prior list transplantation ( order secure MELD exception ) . In case , could time lapse 3 month monitor tumor growth , time lapse 9 month time transplantation . 6 . Patients TIPS Portal Vein Thrombosis may include . 1 . Inability provide inform consent 2 . Known hypersensitivity serious adverse reaction study drug 3 . Age &lt; 18 &gt; 80 year 4 . Pregnancy determine subject reporting urine dipstick test screen . 5 . Other underlie chronic liver disease example would exclude patient participate include limited nonalcoholic liver disease , alcoholic liver disease , hepatitis B , hemochromatosis , autoimmune liver disease . 6 . Serious underlie medical condition example include limited unstable cardiovascular , coronary , pulmonary disease include right left side heart failure , active malignancy HCC , serious infection . 7 . Estimated creatinine clearance &lt; 30 mL min1 1.73 m2 surface area ( BSA ) 8 . Hemoglobin &lt; 10 g/dL 9 . Neutrophils &lt; 500 /μL 10 . Platelets &lt; 50,000 /μL 11 . Bilirubin &gt; 4 mg/dL 12 . Albumin &lt; 2.8 g/dL 13 . Blood Clotting : International Normalised Ratio ( INR ) &gt; 2 14 . MELD &gt; 10 15 . ChildTurcottePugh class B C ; , CTP score &gt; 7 16 . Conditions would affect absorption orally administer cholate use HepQuant® test , extensive intestinal resection , diabetic gastroparesis , ileal disease resection . 17 . Concomitant use betablocker ACE inhibitor 18 . Subjects take medication significant drug drug interaction relate study medication ( sofosbuvir , simeprevir , ribavirin ) discontinue substitute medication , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>